Table 2.
Cox regression analysis of AACS for the primary outcome (non-fatal CV events and all-cause death).
| AACS | Events, n (%) | Model 1 | Model 2 | Model 3 | Model 4 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CIs) |
p Value | HR (95% CIs) |
p Value | HR (95% CIs) |
p Value | HR (95% CIs) |
p Value | |||
| Composite CV events | 0 | 119 (8.8) | Reference | Reference | Reference | Reference | ||||
| 1–2 | 54 (15.5) | 1.921 (1.344, 2.745) |
<0.001 | 1.280 (0.915, 1.789) |
0.149 | 1.144 (0.797, 1.643) |
0.464 | 1.169 (0.806, 1.696) |
0.411 | |
| 3–4 | 27 (16.2) | 1.696 (1.053, 2.734) |
0.030 | 0.961 (0.619, 1.493) |
0.860 | 0.834 (0.514, 1.353) |
0.462 | 0.859 (0.524, 1.408) |
0.546 | |
| 5–6 | 22 (23.9) | 3.134 (1.924, 5.107) |
<0.001 | 1.175 (0.722, 1.910) |
0.516 | 1.062 (0.632, 1.783) |
0.821 | 1.155 (0.680, 1.962) |
0.593 | |
| ≥7 | 40 (32.8) | 4.867 (3.320, 7.135) |
<0.001 | 1.631 (1.095, 2.430) |
0.0161 | 1.718 (1.129, 2.614) |
0.012 | 1.888 (1.219, 2.923) |
0.004 | |
Model 1, unadjusted model. Model 2, model 1 + adjusted for age, sex, Charlson comorbidity index, primary renal disease, current smoking status, medication (ACEi/ARBs, diuretics, number of anti-HTN drugs, statins), BMI, and SBP. Model 3, model 2 + adjusted for hemoglobin, albumin, fasting glucose, HDL-C, TG, 25(OH) vitamin D, hs-CRP, GFR and spot urine ACR. Model 4, model 3 + adjusted for LVEF and categorized E/e’ at the baseline. Abbreviations: AACS, abdominal aortic calcification score; CI, confidence interval; CV, cardiovascular; HR, hazard ratio.